Objectives of the web portal


To consult the programme timeline, click here

The objective of the National Antibiotic Resistance Portal is to give visibility to French research in the field of antibiotic resistance and enable access to studies and information led by the research alliances (AllEnvi, Aviesan, Athena), by the research organisations and institutes (including their laboratories and platforms), the structures and infrastructures funded as part of the Investments for the Future Programme (Programme d’Investissements d’Avenir), the funding agencies, the European and international actions, the private sector(pharmaceutical industries and start-ups) and the healthcare industry unions. The portal also endeavours to facilitate and ensure the continuity and sharing of information issued by the ministries and the national Public Health Agency (Santé publique France) in charge of surveillance.

The mail aims of the portal are:

  • identifying the various forces present in the areas of fundamental and applied research, environmental, veterinary and clinical research, public health and cross-disciplinary research, human, economic and social sciences research, including industries (existing pharmaceutical and veterinary companies as well as startups);
  • creating and maintaining a freely-accessible and interoperable database of the various (public-private) funded research programmes and actors giving rise to calls for expression of interest or calls for projects in the field of antibiotic resistance;
  • gathering and interconnecting the very broad spectrum of competences and expertise present in France to facilitate the coordination of research activities centred around concerted actions, with a One Health approach between public and private sector actors and/or patient associations and national health insurance.

To achieve these objectives, the interface is centred around:

  • an overview of France’s research actors through:
    1. an inventory of the professionals, centres and networks involved in antibiotic resistance surveillance, in human, animal and environmental health;
    2. a database of research laboratories (public and private), to facilitate the reinforcement and creation of collaborations between different sectors;
    3. relationship mapping of the major fields of public and private research expertise, and of collaborations between European and international teams, derived from the creation of a bibliometric database. An annual update of this mapping will add an evolving overview of the research activities;
  • a scientific literature watch monitoring the major national and international advances and breakthroughs in the field of antibiotic resistance;
  • the publication of various events (training, seminars, conferences), employment and training opportunities, studies in preparation, ongoing or completed, patents and calls for projects on a single website to facilitate information-sharing, upskilling and the pooling of knowledge;
  • the possibility for those with private access to automatically add elements to the website (news, publications, jobs, etc.);
  • the shared and secure safeguarding of data.


To give a dynamic and evolving overview of antibiotic resistance research and activities, a chronological summary of the main national and international initiatives, or international initiatives with a French involvement from January 2012 to date is provided below. These actions reveal an uptake in awareness of antibiotic resistance both in France and other countries, starting with the European Commission’s launch of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) in 2012, which has mobilised 28 Member States so far (including France), aimed at funding and coordinating research. In France, the Carlet report, published in 2015, which presents the principal recommendations for reducing antibiotics consumption, constitutes the first of a series of national measures to confront the issue.